Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)
- PMID: 21982313
- DOI: 10.1016/j.jacc.2011.07.020
Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)
Abstract
Objectives: We hypothesized that reductions in left atrial volume (LAV) with a cardiac resynchronization therapy-defibrillator (CRT-D) would translate into a subsequent reduction in the risk of atrial tachyarrhythmias (AT).
Background: There is limited information regarding the effect of CRT-D on the risk of AT.
Methods: Percent reduction in LAV at 1 year following CRT-D implantation (pre-specified as low [lowest quartile: <20% reduction in LAV] and high [≥20% reduction in LAV] response to CRT-D) were related to the risk of subsequent AT (comprising atrial fibrillation, atrial flutter, atrial tachycardia, and supraventricular tachyarrhythmias) among patients enrolled in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy).
Results: The cumulative probability of AT 2.5 years after assessment of echocardiographic response was lowest among high LAV responders to CRT-D (3%) and significantly higher among both low LAV responders to CRT-D (9%) and implantable cardioverter-defibrillator-only patients (7%; p = 0.03 for the difference among the 3 groups). Consistently, multivariate analysis showed that high LAV responders to CRT-D experienced a significant 53% (p = 0.01) reduction in the risk of subsequent AT as compared with implantable cardioverter-defibrillator-only patients, whereas low LAV responders did not derive a significant risk reduction with CRT-D therapy (hazard ratio [HR]: 1.05 [95% confidence interval (CI): 0.54 to 2.00]; p = 0.89). Patients who developed in-trial AT experienced significant increases in the risk for both the combined endpoint of heart failure or death (HR: 2.28 [95% CI: 1.45 to 3.59]; p < 0.001) and the separate occurrence of all-cause mortality (HR: 1.89 [95% CI: 1.08 to 3.62]; p = 0.01).
Conclusions: In the MADIT-CRT study, favorable reverse remodeling of the left atrium with CRT-D therapy was associated with a significant reduction in risk of subsequent AT. (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271).
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy).J Am Coll Cardiol. 2011 Jun 14;57(24):2416-23. doi: 10.1016/j.jacc.2010.12.041. J Am Coll Cardiol. 2011. PMID: 21658562 Clinical Trial.
-
The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).J Am Coll Cardiol. 2014 Apr 1;63(12):1190-1197. doi: 10.1016/j.jacc.2013.10.074. Epub 2013 Dec 11. J Am Coll Cardiol. 2014. PMID: 24333490 Clinical Trial.
-
Cardiac resynchronization therapy is associated with reductions in left atrial volume and inappropriate implantable cardioverter-defibrillator therapy in MADIT-CRT.Heart Rhythm. 2014 Jun;11(6):1001-7. doi: 10.1016/j.hrthm.2014.01.033. Epub 2014 Feb 4. Heart Rhythm. 2014. PMID: 24502968
-
Lessons learned from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).Trends Cardiovasc Med. 2016 Feb;26(2):137-46. doi: 10.1016/j.tcm.2015.04.013. Epub 2015 Apr 30. Trends Cardiovasc Med. 2016. PMID: 26051208 Review.
-
Risk of ventricular arrhythmia in cardiac resynchronization therapy responders and super-responders: a systematic review and meta-analysis.Europace. 2021 Aug 6;23(8):1262-1274. doi: 10.1093/europace/euaa414. Europace. 2021. PMID: 33496319
Cited by
-
Reverse Atrial Remodeling in Heart Failure With Recovered Ejection Fraction.J Am Heart Assoc. 2023 Jan 17;12(2):e026891. doi: 10.1161/JAHA.122.026891. Epub 2023 Jan 16. J Am Heart Assoc. 2023. PMID: 36645090 Free PMC article.
-
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment.Eur J Heart Fail. 2022 Jun;24(6):959-975. doi: 10.1002/ejhf.2562. Epub 2022 Jun 6. Eur J Heart Fail. 2022. PMID: 35598167 Free PMC article. Review.
-
Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis.Curr Cardiol Rep. 2013 Feb;15(2):330. doi: 10.1007/s11886-012-0330-6. Curr Cardiol Rep. 2013. PMID: 23299710 Free PMC article.
-
Atrial fibrillation in heart failure.Curr Heart Fail Rep. 2012 Dec;9(4):309-18. doi: 10.1007/s11897-012-0108-6. Curr Heart Fail Rep. 2012. PMID: 22864857 Review.
-
Cardiac Resynchronization Therapy and Left Atrial Remodeling: A Novel Insight?Biomedicines. 2023 Apr 12;11(4):1156. doi: 10.3390/biomedicines11041156. Biomedicines. 2023. PMID: 37189774 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials